Robert M. Rifkin

Rocky Mountain Cancer Centers — United States

Medicine · Health Sciences

34h-index4.6kcitations257works12.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(188), Protein Degradation and Inhibitors(97), Cancer Treatment and Pharmacology(57), Peptidase Inhibition and Analysis(41), Chronic Lymphocytic Leukemia Research(30)

Publications255 total

Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income
Blood·2025
Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
Clinical Lymphoma Myeloma & Leukemia·2025
MM-405: Optec/Optal: A Phase 2 Study to Evaluate Outpatient (OP) Step-Up Administration of Teclistamab (Tec) or Talquetamab (Tal) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-405 Optec/Optal: A Phase 2 Study to Evaluate Outpatient (OP) Step-Up Administration of Teclistamab (Tec) or Talquetamab (Tal) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
Frontiers in Oncology·2025· 2 citedOpen Access
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
The Lancet Oncology·2025· 7 cited
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody
Clinical Lymphoma Myeloma & Leukemia·2024· 7 citedOpen Access
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
Blood Cancer Journal·2024· 3 citedOpen Access
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry
Clinical Lymphoma Myeloma & Leukemia·2024· 4 citedOpen Access
<i>In-</i>class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received
Blood·2024Open Access
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Blood·2024· 11 cited
Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
Blood·2024· 5 cited
P-175 Real-World Minimal Residual Disease Testing Patterns: Findings From the Connect® MM Registry
Clinical Lymphoma Myeloma & Leukemia·2024
P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Nature Genetics·2024· 58 citedOpen Access
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry
Clinical Lymphoma Myeloma & Leukemia·2024
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 4 cited
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine·2024· 127 cited
Plain Language Review: What are Biosimilar Medicines and how Can they be Used to Treat People with Cancer?
Future Oncology·2023· 2 citedOpen Access
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry
Practical Radiation Oncology·2023· 1 cited
page 1 of 13Next →

Frequent Co-authors

Rafat Abonour(11), Ian W. Flinn(9), James W. Hardin(9), Mohit Narang(9), Jesús G. Berdeja(8), Kathleen Toomey(8), Shankar Srinivasan(8), Howard R. Terebelo(8), Saad Z. Usmani(7), Sundar Jagannath(7), Rubén Niesvizky(7), Brian G.M. Durie(7), Shaji Kumar(6), Paul G. Richardson(6), Parameswaran Hari(6), Stephen J. Noga(6), S. Vincent Rajkumar(6), Jatin J. Shah(6), Amani Kitali(6), Cristina Gasparetto(6)